535 related articles for article (PubMed ID: 7502710)
1. Regulation of plasminogen activation, matrix metalloproteinases and urokinase-type plasminogen activator-mediated extracellular matrix degradation in human osteosarcoma cell line MG63 by interleukin-1 alpha.
de Bart AC; Quax PH; Löwik CW; Verheijen JH
J Bone Miner Res; 1995 Sep; 10(9):1374-84. PubMed ID: 7502710
[TBL] [Abstract][Full Text] [Related]
2. The effect of IL-1alpha on the expression of matrix metalloproteinases, plasminogen activators, and their inhibitors in osteoblastic ROS 17/2.8 cells.
Fujisaki K; Tanabe N; Suzuki N; Mitsui N; Oka H; Ito K; Maeno M
Life Sci; 2006 Mar; 78(17):1975-82. PubMed ID: 16313928
[TBL] [Abstract][Full Text] [Related]
3. In vitro effects of interleukin 1 on the synthesis of metalloproteases, TIMP, plasminogen activators and inhibitors in human articular cartilage.
Martel-Pelletier J; Zafarullah M; Kodama S; Pelletier JP
J Rheumatol Suppl; 1991 Feb; 27():80-4. PubMed ID: 1851231
[TBL] [Abstract][Full Text] [Related]
4. Modulation of tissue plasminogen activator and plasminogen activator inhibitor-1 by transforming growth factor-beta in human retinal glial cells.
Schacke W; Beck KF; Pfeilschifter J; Koch F; Hattenbach LO
Invest Ophthalmol Vis Sci; 2002 Aug; 43(8):2799-805. PubMed ID: 12147618
[TBL] [Abstract][Full Text] [Related]
5. Modulation of mRNA levels for urinary- and tissue-type plasminogen activator and plasminogen activator inhibitors 1 and 2 in human fibroblasts by interleukin 1.
Michel JB; Quertermous T
J Immunol; 1989 Aug; 143(3):890-5. PubMed ID: 2501387
[TBL] [Abstract][Full Text] [Related]
6. Regulation by epidermal growth factor of human squamous cell carcinoma plasminogen activator-mediated proteolysis of extracellular matrix.
Niedbala MJ; Sartorelli AC
Cancer Res; 1989 Jun; 49(12):3302-9. PubMed ID: 2497975
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of proteolytic activity in 12-O-tetradecanoyl-phorbol-13-acetate-induced K562 leukemia cell cultures: depletion of active urokinase by excess type 1 plasminogen activator inhibitor.
Alitalo R; Andersson LC; Tapiovaara H; Sistonen L; Vaheri A; Stephens R
J Cell Physiol; 1989 Jul; 140(1):119-30. PubMed ID: 2500450
[TBL] [Abstract][Full Text] [Related]
8. Transforming growth factor beta inhibits plasminogen activator (PA) activity and stimulates production of urokinase-type PA, PA inhibitor-1 mRNA, and protein in rat osteoblast-like cells.
Allan EH; Zeheb R; Gelehrter TD; Heaton JH; Fukumoto S; Yee JA; Martin TJ
J Cell Physiol; 1991 Oct; 149(1):34-43. PubMed ID: 1834680
[TBL] [Abstract][Full Text] [Related]
9. Modulation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 expression by U-937 mononuclear phagocytes. Effects of 1 alpha, 25-dihydroxyvitamin D3 and phorbol ester.
Gyetko MR; Webb AC; Sitrin RG
J Immunol; 1988 Oct; 141(8):2693-8. PubMed ID: 3139763
[TBL] [Abstract][Full Text] [Related]
10. Urokinase plasminogen activator stimulates function of active forms of stromelysin and gelatinases (MMP-2 and MMP-9) in cirrhotic tissue.
González-Cuevas J; Bueno-Topete M; Armendariz-Borunda J
J Gastroenterol Hepatol; 2006 Oct; 21(10):1544-54. PubMed ID: 16928215
[TBL] [Abstract][Full Text] [Related]
11. ACE inhibition reduces activity of the plasminogen/plasmin and MMP systems in the brain of spontaneous hypertensive stroke-prone rats.
Liebetrau M; Burggraf D; Wunderlich N; Jäger G; Linz W; Hamann GF
Neurosci Lett; 2005 Mar; 376(3):205-9. PubMed ID: 15721222
[TBL] [Abstract][Full Text] [Related]
12. Independent regulation of matrix metalloproteinases and plasminogen activators in human fibrosarcoma cells.
Lim YT; Sugiura Y; Laug WE; Sun B; Garcia A; DeClerck YA
J Cell Physiol; 1996 May; 167(2):333-40. PubMed ID: 8613475
[TBL] [Abstract][Full Text] [Related]
13. Effect of phorbol ester and cytokines on matrix metalloproteinase and tissue inhibitor of metalloproteinase expression in tumor and normal cell lines.
Mackay AR; Ballin M; Pelina MD; Farina AR; Nason AM; Hartzler JL; Thorgeirsson UP
Invasion Metastasis; 1992; 12(3-4):168-84. PubMed ID: 1284126
[TBL] [Abstract][Full Text] [Related]
14. Increased TIMP/MMP ratio in varicose veins: a possible explanation for extracellular matrix accumulation.
Badier-Commander C; Verbeuren T; Lebard C; Michel JB; Jacob MP
J Pathol; 2000 Sep; 192(1):105-12. PubMed ID: 10951407
[TBL] [Abstract][Full Text] [Related]
15. Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts.
Allan EH; Martin TJ
J Cell Physiol; 1995 Dec; 165(3):521-9. PubMed ID: 7593231
[TBL] [Abstract][Full Text] [Related]
16. Expression and localisation of extracellular matrix degrading proteases and their inhibitors during the oestrous cycle and after induced luteolysis in the bovine corpus luteum.
Kliem H; Welter H; Kraetzl WD; Steffl M; Meyer HH; Schams D; Berisha B
Reproduction; 2007 Sep; 134(3):535-47. PubMed ID: 17709571
[TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor induction of urokinase-type plasminogen activator in human endothelial cells.
Niedbala MJ; Stein M
Biomed Biochim Acta; 1991; 50(4-6):427-36. PubMed ID: 1801706
[TBL] [Abstract][Full Text] [Related]
18. Effect of compressive force on the expression of MMPs, PAs, and their inhibitors in osteoblastic Saos-2 cells.
Mitsui N; Suzuki N; Koyama Y; Yanagisawa M; Otsuka K; Shimizu N; Maeno M
Life Sci; 2006 Jul; 79(6):575-83. PubMed ID: 16516240
[TBL] [Abstract][Full Text] [Related]
19. Activation systems for latent matrix metalloproteinase-2 are upregulated immediately after focal cerebral ischemia.
Chang DI; Hosomi N; Lucero J; Heo JH; Abumiya T; Mazar AP; del Zoppo GJ
J Cereb Blood Flow Metab; 2003 Dec; 23(12):1408-19. PubMed ID: 14663336
[TBL] [Abstract][Full Text] [Related]
20. Effects of nicotine and lipopolysaccharide on the expression of matrix metalloproteinases, plasminogen activators, and their inhibitors in human osteoblasts.
Katono T; Kawato T; Tanabe N; Tanaka H; Suzuki N; Kitami S; Morita T; Motohashi M; Maeno M
Arch Oral Biol; 2009 Feb; 54(2):146-55. PubMed ID: 18986645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
